“We have attempted a very disciplined approach. We never went for over concentrated investment into any sector or stock and wherever we felt there are massive macro headwinds or challenges. We have exited those sectors or stocks. For example, we exited IT and pharma in December 2020 or early 2021, seeing the challenges.”
Subscribe To Our Free Newsletter |